

Haematologica
HAEMATOL/2018/212837
Version 3

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia

Othman Al-Sawaf, Carmen Diana Herling, Udo Holtick, Christoph Scheid, Paula Cramer, Stephanie Sasse, Bastian von Tresckow, Armin Tuchscherer, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, and Lukas P. Frenzel

Disclosures: OA, PC, BE, MH, and LPF have received honoraria, consulting fees and research support from Abbvie and Roche. CDH has received research support from Roche. The other authors declare no relevant conflicts of interest.

Contributions: OA, CDH, BE, MH and LPF analyzed the data and wrote the paper. OA, CDH, UH, CS, PC, SS, BvT, AT, BE, MH, LPF treated and managed the patients. All co-authors reviewed and corrected the manuscript.